First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort

被引：0
|
作者：
Yu, Jinming
Sun, Yuping
Dang, Qi
Zhang, Yan
Du, Jintong
Wei, Yonggang
Ye, Fei
Liu, Rui
Zhao, Qi
Li, Zhiyong
机构：
[1] Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China
[2] Shandong Canc Hosp, Jinan, Peoples R China
[3] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[4] Shandong First Med Univ, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[5] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China
[6] Chengdu Baiyu Pharmaceut Co Ltd, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial
    Bos, Eelke M. M.
    Binda, Elena
    Verploegh, Iris S. C.
    Wembacher, Eva
    Hoefnagel, Daphna
    Balvers, Rutger K. K.
    Korporaal, Anne L. L.
    Conidi, Andrea
    Warnert, Esther A. H.
    Trivieri, Nadia
    Visioli, Alberto
    Zaccarini, Paola
    Caiola, Laura
    van Wijck, Rogier
    van der Spek, Peter
    Huylebroeck, Danny
    Leenstra, Sieger
    Lamfers, Martine L. M.
    Ram, Zvi
    Westphal, Manfred
    Noske, David
    Legnani, Federico
    DiMeco, Francesco
    Vescovi, Angelo Luigi
    Dirven, Clemens M. F.
    MOLECULAR CANCER, 2023, 22 (01)
  • [32] Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study
    Lin, Chih-Wei
    Dutta, Sandeep
    Asatryan, Armen
    Chiu, Yi-Lin
    Wang, Haoyu
    Ii, Jack Clifton
    Campbell, Andrew
    Liu, Wei
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (02) : 645 - 651
  • [33] First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers
    Rein-Hedin, Erik
    Sjoberg, Folke
    Waters, Susanna
    Sonesson, Clas
    Waters, Nicholas
    Huss, Fredrik
    Tedroff, Joakim
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (12): : 1485 - 1494
  • [34] First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management
    Moss, Laurence M.
    Berends, Cecile L.
    van Brummelen, Emilie M. J.
    Kamerling, Ingrid M. C.
    Klaassen, Erica S.
    Bergmann, Kirsten
    Ville, Vanessa
    Juarez-Perez, Victor
    Benichou, Annie-Claude
    Groeneveld, Geert Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 103 - 114
  • [35] A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants
    Lim, Chay Ngee
    Kantaridis, Constantino
    Huyghe, Isabelle
    Gorman, Donal
    Berasi, Stephen
    Sonnenberg, Gabriele E.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (04):
  • [36] A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers
    Hu, Chaoying
    Li, Jian
    Sun, Wanling
    Zhang, Lan
    BLOOD, 2022, 140 : 2447 - 2448
  • [37] A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia
    Sivapalaratnam, Suthesh
    Austin, Steve
    Lorch, Ulrike
    York, Thomas
    Want, Andrew
    Gosnell, Ashley
    Gandhi, Prafull S.
    Ostergaard, Henrik
    Bjornson, Erik
    O'Meara, Tara
    Sorensen, Benny
    Schutgens, Roger E. G.
    Rea, Catherine
    BLOOD, 2023, 142
  • [38] First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody
    Espie, Pascal
    He, YanLing
    Koo, Phillip
    Sickert, Denise
    Dupuy, Cyrielle
    Chokote, Edwige
    Schuler, Roland
    Mergentaler, Heidi
    Ristov, Jacinda
    Milojevic, Julie
    Verles, Aurelie
    Groenewegen, Andrea
    Auger, Anita
    Avrameas, Alexandre
    Rotte, Michael
    Colin, Laurence
    Tomek, Charles S.
    Hernandez-Illas, Martha
    Rush, James S.
    Gergely, Peter
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (02) : 463 - 473
  • [39] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY: RESULTS FROM THE FIRST-IN-HUMAN SINGLE DOSE ESCALATION STUDY IN HEALTHY VOLUNTEERS
    Khlyabova, P.
    Eremeeva, A.
    Lutckii, A.
    Dokukina, E.
    Chemyaeva, E.
    Ivanov, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 884 - 885
  • [40] Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
    Playford, Elliott Geoffrey
    Munro, Trent
    Mahler, Stephen M.
    Elliott, Suzanne
    Gerometta, Michael
    Hoger, Kym L.
    Jones, Martina L.
    Griffin, Paul
    Lynch, Kathleen D.
    Carroll, Heidi
    El Saadi, Debra
    Gilmour, Margaret E.
    Hughes, Benjamin
    Hughes, Karen
    Huang, Edwin
    de Bakker, Christopher
    Klein, Reuben
    Scher, Mark G.
    Smith, Ina L.
    Wang, Lin-Fa
    Lambert, Stephen B.
    Dimitrov, Dimiter S.
    Gray, Peter P.
    Broder, Christopher C.
    LANCET INFECTIOUS DISEASES, 2020, 20 (04): : 445 - 454
12345